Novo Nordisk CagriSema Trial Shows 25% Weight Loss in Women
Phase 3 results for investigational CagriSema showed an average 25% body-weight decrease after 68 weeks in more than 2,300 overweight or obese women.
Novo Nordisk A/S reported new phase 3 results for its investigational CagriSema obesity medicine. Over 68 weeks, the treatment produced an average body-weight reduction of 25% among overweight or obese women. The analysis included more than 2300 women.